The US Food and Drug Administration (FDA) has approved dexmedetomidine (Igalmi) sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.
Teva Pharmaceuticals announced the approval, describing dexmedetomidine as the first FDA-approved treatment specifically indicated for self-administration at home during agitation episodes associated with these conditions. The drug, described as a highly selective alpha-2 adrenergic receptor agonist, was previously approved for use under health care provider supervision.
The expanded approval was supported by SERENITY At-Home, a phase 3, randomized, double-blind, placebo-controlled trial evaluating safety and tolerability during self-administration outside supervised settings. Of 246 randomized adults, 208 received study treatment, including 102 assigned to dexmedetomidine and 106 to placebo. Across both groups, 2,437 agitation episodes were treated.
According to Teva, tolerability remained consistent during repeat dosing over 12 weeks, with no discontinuations due to adverse events in the dexmedetomidine group. The study poster reported somnolence, including fatigue, after the first treated episode in 22.5% of dexmedetomidine recipients vs 17% receiving placebo, dry mouth in 6.9% vs 0.9%, and dizziness in 4.9% vs 0.9%. It also reported significantly higher rates of complete agitation resolution with dexmedetomidine than placebo. However, the trial was not powered to assess efficacy.
In the earlier phase 3 SERENITY I and II trials conducted in supervised settings, dexmedetomidine produced an average reduction of approximately 9.6 points on the Positive and Negative Syndrome Scale-Excited Component at 2 hours vs 4.9 points with placebo.
The company's safety information warns that dexmedetomidine can cause hypotension, orthostatic hypotension, and bradycardia. It also identifies cardiovascular conditions, a history of syncope, hepatic impairment, and concomitant use of sedating medications as relevant precautions.
Commercialization plans for the at-home indication have not yet been announced.
